Immunic (IMUX) shares rose more than 14% in premarket trading after it reported "positive" outcomes from an interim analysis of its phase 3 trial of vidofludimus calcium for the treatment of relapsing multiple sclerosis.
Based on the interim analysis, an independent data monitoring committee has recommended that the trials should continue as planned. Completion is expected in 2026.
The trial includes two identical multicenter, randomized, double-blind phase 3 trials enrolling about 1,050 each designed to evaluate the efficacy, safety and tolerability of vidofludimus calcium versus placebo in relapsing multiple sclerosis patients.
The primary endpoint for both trials is time to first relapse in up to 72 weeks. Secondary endpoints include time to worsening of disability.
Price: 1.8000, Change: +0.25, Percent Change: +16.13
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.